Rein Therapeutics, Inc (RNTX)

Rein Therapeutics reported its first quarter 2025 financial results in May 2025 and initiated the Phase 2 RENEW trial of LTI-03 in patients with IPF. The company announced the issuance of two U.S. patents in April 2025, covering novel formulation and administration methods of dry powder LTI-03 for respiratory diseases. A publication in the peer-reviewed journal Biomedicines in April 2025 highlighted the therapeutic potential of a Caveolin-1-related peptide (LTI-2355) in IPF and post-acute sequelae of COVID fibrosis. As of April 10, 2026, the stock price was $1.49. The company's last reported EPS was -$1.09 on March 26, 2026.

The demand for Rein Therapeutics' products and services is not typically subject to seasonal fluctuations. Demand for its potential future products would be driven by disease prevalence, clinical trial outcomes, regulatory approvals, and physician adoption, rather than seasonal patterns. The company's current activities are centered on research and clinical development rather than commercial product sales.

Rein Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for unmet medical needs in orphan pulmonary and fibrosis indications, primarily in the United States. Their lead product candidate, LTI-03, is in Phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF) and has received Orphan Drug Designation in the U.S. LTI-01 has completed Phase 1b and Phase 2a clinical trials for loculated pleural effusions (LPE) and has been granted Orphan Drug Designation in both the United States and the European Union, as well as Fast Track Designation in the U.S. The company also has preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications. LTI-05 is an epithelial sodium channel also being developed for the treatment of cystic fibrosis.

Rein Therapeutics, Inc. is headquartered in Austin, Texas, United States. The company's primary focus is addressing unmet medical needs in the United States. LTI-01 has also received Orphan Drug Designation in the European Union, indicating potential future activities or market considerations in that region.

Rein Therapeutics has made announcements that could positively impact its reputation, including the initiation of a Phase 2 clinical trial for LTI-03 and the granting of U.S. patents for LTI-03. A scientific publication highlighting the therapeutic potential of one of its peptides also contributes to its scientific standing. The company's focus on orphan diseases with unmet medical needs generally garners a positive perception.

The provided search results do not contain specific information about the major institutional and individual owners of Rein Therapeutics, Inc.